Last updated: February 20, 2026
What is NDC 53451-0101?
NDC 53451-0101 corresponds to a branded formulation of a specific pharmaceutical. Current sources identify it as a drug marketed for [indication], with a dosage form of [form], and a typical strength of [strength].
Market Overview
The drug operates within the [Therapeutic Area], competing against [number] of similar medications. Key competitors include [list of major drugs], with market shares of approximately [percentages].
Market Size
The global market for this therapeutic class was valued at approximately USD [value] in 2022. The U.S. accounts for over [percent]% of revenue, with an estimated USD [value] sales volume. Growth rate projections average [percent]% annually through 2027.
Key Stakeholders
- Pharmaceutical manufacturers: Company A (holder of NDC 53451-0101), Company B, and others.
- Healthcare providers: Specialists in [specialties], with prescribing habits influenced by guidelines and formulary criteria.
- Payers: Medicare, private insurers, and pharmacy benefit managers (PBMs). Coverage policies impact launch and pricing strategies.
Regulatory Status
The drug has received FDA approval on [date], with current patent expiration in [year]. Market exclusivity is scheduled to end in [year], after which biosimilar or generic competition is expected.
Price Dynamics and Projections
Current Pricing
The average wholesale price (AWP) for the drug stands at USD [value] per unit. The average wholesale acquisition cost (WAC) is USD [value], with retail prices averaging USD [value] per unit. Reimbursement rates vary by payer, with negotiated discounts lowering effective payer costs.
Pricing Trends
Over the past 12 months, prices have increased by approximately [percent]% due to:
- Rising manufacturing costs.
- Inflation-adjusted supply chain adjustments.
- Demand shifts driven by clinical guideline updates.
Factors Influencing Future Pricing
- Patent expiration: Expected in [year], likely leading to price erosion.
- Market entry of generics/biosimilars: Projected to reduce prices by 30-50%, based on historical data.
- Regulatory changes: Potential drug pricing reforms could impose price ceilings, impacting profit margins.
- Remuneration and formularies: Payers' formulary preferences and tiering influence final patient costs.
Price Projections (Next 5 Years)
| Year |
Estimated Average Price per Unit |
Description |
| 2023 |
USD [value] |
Current market prices. |
| 2024 |
USD [value] ± 5% |
Slight increase due to inflation and demand. |
| 2025 |
USD [value] - 10% |
Entry of biosimilars reduces prices. |
| 2026 |
USD [value] - 20% |
Price reductions stabilize as market matures. |
| 2027 |
USD [value] - 25-40% |
Competition peaks; price plateau expected. |
Revenue Forecast
Assuming a market penetration rate of [percent]% and an average unit price decrease, projected annual revenue is estimated at USD [value] in 2027, representing a decline from USD [value] in 2023 due to generic competition.
Market Risks
- Regulatory delays affecting patent lives.
- Accelerated biosimilar approval pathways.
- Shifts in clinical guidelines favoring alternative therapies.
- Payer resistance to high-cost branded drugs.
Strategic Implications
Investors should consider patent expiry timelines and competitive positioning when evaluating the drug's valuation. Manufacturers should prepare for price compression and focus on lifecycle extension strategies, such as indications expansion or formulation updates.
Key Takeaways
- The drug’s current market size is significant within its therapeutic class but faces impending generic competition.
- Prices are volatile, influenced by patent status, supply chain factors, and payer negotiations.
- Price declines of up to 50% are expected post-generic entry.
- Market growth will slow as biosimilar competition intensifies.
- Innovation and regulatory strategies will be critical for maintaining pricing power.
FAQs
1. When is patent expiration for NDC 53451-0101?
Patent expiration is scheduled for [year], after which biosimilars and generics can enter the market.
2. What is the expected impact of biosimilar entry on prices?
Biosimilar competition is projected to reduce prices by 30-50% within two years of market entry.
3. How does payer negotiation affect net prices?
Negotiated discounts via PBMs and insurance plans often lower net prices significantly from list prices.
4. Are there upcoming regulatory changes that could influence pricing?
Potential legislation targeting drug pricing transparency and caps could impact profit margins.
5. What are growth opportunities beyond the current indication?
Expansion into new indications, formulations, or delivery methods offers potential for revenue growth.
References
- IQVIA. (2022). The Global Use of Medicine in 2022.
- FDA. (2022). Drug Approvals and Regulatory Milestones.
- EvaluatePharma. (2022). World Preview 2022: Outlook to 2027.
- Centers for Medicare & Medicaid Services. (2022). Drug Pricing and Reimbursement Data.
- Pharmaceutical Research and Manufacturers of America (PhRMA). (2022). Market Trends Report.
Note: Specific values, dates, and market data should be verified against current industry reports for accuracy.
